This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Editing/proofreading
Expertise
Specializes in:
Medical (general)
Medical: Health Care
Rates
Portfolio
Sample translations submitted: 1
English to Spanish: Protocolo clínico General field: Medical Detailed field: Medical (general)
Source text - English A 2 × 2 factorial, randomised, open-label
trial to determine the clinical and costeffectiveness of hypertonic saline (HTS 6%)
and carbocisteine for airway clearance
versus usual care over 52 weeks in adults
with bronchiectasis: a protocol for the
CLEAR clinical trial
ㅤㅤㅤ
Background
Background information
Bronchiectasis (BE) is a debilitating chronic illness
caused by irreversible dilatation, thickening and sac-like
formations in bronchial walls. Patients usually suffer
from a persistent cough, chronic daily sputum expectoration, recurrent chest infections and poor health-related
quality of life (HRQoL) [1, 2]. Current estimates suggest
around 5 in 1000 people in the UK have BE [3, 4] with
higher numbers of patients being diagnosed with BE due
to increased use of high-resolution computed tomography (HRCT) [5]. Mortality in the 52 weeks after a BErelated exacerbation is as high as 30% [6]. Morbidity is
also high and UK hospitals admission data indicate that
BE was the primary diagnosis in 1 in 1800 admissions,
with a sevenfold increase in hospital bed days needed for
treating BE in the first decade of the 21st century [7, 8].
Mucus hypersecretion is a clinical feature of BE. Airway mucosal infection often gives rise to inflammatory
mediators [9], including neutrophil-derived DNA and
filamentous actin, in addition to apoptotic cells and cellular debris that may collectively increase mucus production and viscosity. This mucus retention aids bacterial
infection that can lead to pulmonary exacerbations,
which further develops the “viscous cycle” of mucus retention, infection, inflammation and tissue damage [10].
Mucoactive drugs target this cycle by potentially increasing the ability to expectorate sputum and/or decrease
mucus hypersecretion. Mucoactive drugs are classified in
terms of their proposed primary mechanism of action:
expectorants induce mucus expulsion, mucoregulators
reduce mucus secretion, mucolytics decrease viscosity
and mucokinetics increase cilia activity.
Translation - Spanish Protocolo para el ensayo clínico CLEAR, con diseño factorial 2×2, aleatorizado y sin anonimatos para determinar la costo-efectividad de la solución salina hipertónica (SH 6 %) y de la carbocisteína en la depuración de las vías respiratorias en comparación con los fármacos de uso común durante 52 semanas en adultos con bronquiectasia
Introducción
Información general
ㅤㅤㅤ
La bronquiectasia (BQ) es una enfermedad crónica debilitante causada por el ensanchamiento y la dilatación irreversible y sacular de las paredes bronquiales. Los pacientes tienden a sufrir tos constante, expectoración diaria crónica, infecciones respiratorias recurrentes y mala calidad de vida relacionada con la salud (CVRS) [1, 2]. En la actualidad, se estima que aproximadamente 5 de cada 1 000 personas en el Reino Unido padecen BQ [3, 4], la mayoría de ellas diagnosticadas gracias al uso cada vez mayor de las tomografías computadas de alta resolución (TCAR) [5]. La mortalidad en las 52 semanas posteriores a una exacerbación relacionada con BQ asciende al 30 % [6]. Por otra parte, la morbilidad también es alta y, de acuerdo con los datos de ingresos de los hospitales británicos, la BQ es el diagnóstico principal en 1 de cada 1 800 ingresos, cantidad que se septuplica en los días cama que fueron necesarios para tratar la BQ durante la primera década del siglo XXI [7, 8]. La hipersecreción de moco forma parte del cuadro clínico de la BQ. La infección de la mucosa de las vías respiratorias suele dar lugar a los mediadores de la inflamación [9], entre los cuales se incluyen el ADN derivado de neutrófilos y los microfilamentos, además de las células apoptóticas y los residuos celulares que pueden incrementar la producción de moco y su viscosidad. Esta retención de moco potencia la infección bacteriana, lo que puede conducir a exacerbaciones pulmonares y, por consiguiente, contribuir al «ciclo viscoso» de retención de moco, infección, inflamación y daño tisular [10]. Los fármacos mucoactivos se enfocan en romper este ciclo, aumentando de manera potencial la capacidad de expectorar el esputo o disminuir la hipersecreción de moco. Estos fármacos se clasifican según el propósito de su mecanismo de acción primario: los expectorantes inducen la expulsión de moco, los mucorreguladores reducen la secreción de moco, los mucolíticos disminuyen la viscosidad y los mucocinéticos aumentan la actividad de los cilios.
More
Less
Translation education
Bachelor's degree - Translation
Experience
Years of experience: 3. Registered at ProZ.com: May 2021.
I am a professional Translator and Proofreader based in Chile. Since 2021 I have been working in the fields of medicine and healthcare, areas that are of great interest to me. I am constantly learning new ways to expand my knowledge and provide high-quality services. I'm an avid reader and seeker of wisdom, and I always place as much importance on my relationships with my clients as I do on my translations.
"After all, we're here to make the unknown known, to make the other familiar. We're here to make magic with words."
R.F. Kuang
Keywords: english, spanish, translation, proofreading, medicine, health care